Advances in vaccine delivery: transcutaneous immunisation
- 1 June 1999
- journal article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 8 (6) , 797-805
- https://doi.org/10.1517/13543784.8.6.797
Abstract
Needle-free delivery of vaccines has become a global priority. Transcutaneous immunisation (TCI), topical application of vaccine antigens to the skin, can elicit systemic antibody and T-cell responses, suggesting that this new technique may provide a means for vaccination without needles. TCI requires the use of an adjuvant such as cholera toxin added to a vaccine antigen, such as diphtheria toxoid, to induce antibodies to diphtheria toxoid. The adjuvant and antigen are thought to target Langerhans cells, potent antigen-presenting cells found in the superficial layers of the skin. TCI appears to be a highly practical technique for delivery of vaccines that provides unique access to the immune system.Keywords
This publication has 24 references indexed in Scilit:
- Cholera Toxin B Subunit as an Immunomodulator for Mucosal Vaccine DeliveryPublished by Elsevier ,1999
- Bacterial Toxins as Mucosal AdjuvantsPublished by Springer Nature ,1999
- Dendritic Cells: A Link Between Innate and Adaptive ImmunityJournal of Clinical Immunology, 1999
- Taking the Sting Out of Shots: Control of Vaccination-Associated Pain and Adverse ReactionsPediatric Annals, 1998
- Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral imm_unization of mice against Helicobacter felisImmunology, 1998
- Vaccine developmentsNature Medicine, 1998
- Future vaccines and a global perspectiveThe Lancet, 1997
- Early molecular events in the induction phase of contact sensitivity.Proceedings of the National Academy of Sciences, 1992
- INTRADERMAL HEPATITIS B VIRUS VACCINE: IMMUNOGENICITY AND SIDE-EFFECTS IN ADULTSThe Lancet, 1983
- The Fine Structure of the Melanocyte and Melanin Granule**From the Division of Dermatology, (Dr. F. W. Lynch, Director) and the Department of Anatomy, University of Minnesota Medical School, Minneapolis 14, Minnesota.Aided by research grants M-388 and B-782 from the National Institute of Mental Health and the National Institute for Neurologic Diseases and Blindness, U. S. Public Health Service, and by the Graduate Medical Research Fund of the University of Minnesota.Journal of Investigative Dermatology, 1961